Panelists advocate for a streamlined approach to diagnosing KMT2A-rearranged acute myeloid leukemia (AML) that includes standardized testing protocols (cytogenetics, fluorescence in situ hybridization ...

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent ...

DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were ...

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

This interview was originally published as part of MDEdge's Blood & Cancer Podcast series. In this episode, podcast host David Henry, MD, of Pennsylvania Hospital in Philadelphia, spoke with James M.

Co announced that, data were presented at the EHA Meeting in a subset of 59 patients with unfavorable cytogenetics. Of these patients, 28 (47%) had secondary AML, 21 (36%) had de novo AML, and 10 (17% ...

Patients 1 and 2 had bone marrow cytogenetic analyses and reverse transcriptase-polymerase chain reaction (RT-PCR) screening for chromosomal translocations performed at initial presentation. Patient 3 ...